Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Intra-Cellular Therapies showcased robust financial and operational performance for the third quarter of 2024, spearheaded by the growth of their branded drug, CAPLYTA.</li><li>The company reported net sales of $175.2 million, marking a 39% increase compared to the third quarter of 2023.</li><li>This growth trajectory led Intra-Cellular Therapies to revise their 2024 full-year net sales guidance upward to between $665 million and $685 million.</li></ul>

Intra-Cellular Therapies showcased robust financial and operational performance for the third quarter of 2024, spearheaded by the growth of their branded drug, CAPLYTA.The company reported net sales of $175.2 million, marking a 39% increase compared to the third quarter of 2023.This growth trajectory led Intra-Cellular Therapies to revise their 2024 full-year net sales guidance upward to between $665 million and $685 million.

Intra-Cellular Therapies Inc.: An Analysis Of The Commercial Strategy and Market Expansion for CAPLYTA & Key Growth Drivers

<ul><li>Intra-Cellular Therapies reported robust financial and operational results for the second quarter of 2024, underpinned by significant growth in their primary product, CAPLYTA.</li><li>This performance highlights several positive developments and a few areas of consideration for potential investors.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Intra-Cellular Therapies reported robust financial and operational results for the second quarter of 2024, underpinned by significant growth in their primary product, CAPLYTA.This performance highlights several positive developments and a few areas of consideration for potential investors.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Intra-Cellular Therapies Inc.: Preparations for New Pipeline Developments and Indications! - Major Drivers

<ul><li>Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and clinical realms.</li><li>The company reported a significant rise in total revenues, reaching $144.9 million with CAPLYTA net sales alone accounting for $144.8 million, reflecting a 53% growth year-over-year.</li><li>This growth trajectory reaffirms the drug’s strong market acceptance and penetration within its approved indications for bipolar depression and schizophrenia.</li></ul>

Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and clinical realms.The company reported a significant rise in total revenues, reaching $144.9 million with CAPLYTA net sales alone accounting for $144.8 million, reflecting a 53% growth year-over-year.This growth trajectory reaffirms the drug’s strong market acceptance and penetration within its approved indications for bipolar depression and schizophrenia.

Intra-Cellular Therapies Inc.: How They Are Expanding Market Opportunities for CAPLYTA!  - Major Drivers

<ul><li>Intra-Cellular Therapies, during their fourth quarter and full-year 2023 earnings, expressed a positive outlook based on strong and consistent growth throughout the past year.</li><li>Key achievements included establishing CAPLYTA as a significant treatment option for a broad patient population with bipolar depression and schizophrenia, and advancing several of their pipeline programs.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Intra-Cellular Therapies, during their fourth quarter and full-year 2023 earnings, expressed a positive outlook based on strong and consistent growth throughout the past year.Key achievements included establishing CAPLYTA as a significant treatment option for a broad patient population with bipolar depression and schizophrenia, and advancing several of their pipeline programs.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Intra-Cellular Therapies Inc.:  Lumateperone’s market growth in the significant bipolar depression segment & other major drivers

<ul><li>This is our first report on biopharma major, Intra-Cellular Therapies.</li><li>The company reported solid progress in its Q4 and FY2023 results, marking a year characterized by steady growth across the company.</li><li>Central to the year's success was the establishment of CAPLYTA as a vital treatment option for bipolar depression and schizophrenia.</li></ul>

This is our first report on biopharma major, Intra-Cellular Therapies.The company reported solid progress in its Q4 and FY2023 results, marking a year characterized by steady growth across the company.Central to the year's success was the establishment of CAPLYTA as a vital treatment option for bipolar depression and schizophrenia.

Intra-Cellular Therapies Inc.: Initiation Of Coverage - 6 Major Drivers

United States

Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The Company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Iti Inc (ITCI US)

Intra-Cellular Therapies Inc.: An Analysis Of The Commercial Strategy and Market Expansion for CAPLYTA & Key Growth Drivers

Intra-Cellular Therapies showcased robust financial and operational performance for the third quarter of 2024, spearheaded by the growth of their...

Baptista Research

Intra-Cellular Therapies Inc.: Preparations for New Pipeline Developments and Indications! - Major Drivers

Intra-Cellular Therapies reported robust financial and operational results for the second quarter of 2024, underpinned by significant growth in...

Baptista Research

Intra-Cellular Therapies Inc.: How They Are Expanding Market Opportunities for CAPLYTA! - Major Drivers

Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and...

Baptista Research

Intra-Cellular Therapies Inc.: Lumateperone’s market growth in the significant bipolar depression segment & other major drivers

Intra-Cellular Therapies, during their fourth quarter and full-year 2023 earnings, expressed a positive outlook based on strong and consistent...

Baptista Research

Intra-Cellular Therapies Inc.: Initiation Of Coverage - 6 Major Drivers

This is our first report on biopharma major, Intra-Cellular Therapies. The company reported solid progress in its Q4 and FY2023 results, marking a...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)